Ovarian > Ovarian cancer
Select trial for more information
Area under investigation,Ovarian cancer=true
Tumor
Advanced solid tumors (breast cancer, BTCs, ovarian cancer, endometrial cancer, squamous NSCLC)
Trial Identifier
NCT05123482
Phase
I/IIa
Regimen
Puxitatug samrotecan monotherapy; puxitatug samrotecan + rilvegostomig; puxitatug samrotecan + rilvegostomig + palacaparib
HR+/HER2- advanced breast cancer, metastatic high-grade serous ovarian cancer
NCT06188520
AZD8421; AZD8421 + camizestrant + abemaciclib; AZD8421 + camizestrant + ribociclib; AZD8421 + camizestrant + palbociclib
HER2-expressing (IHC 3+/2+/1+) advanced high-grade ovarian cancer
NCT06819007
III
T-DXd + bevacizumab vs bevacizumab
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world. This study is sponsored by Daiichi Sankyo, Inc.
Advanced solid tumors
NCT05797168
Torvutatug samrotecan monotherapy; torvutatug samrotecan + saruparib; torvutatug samrotecan + bevacizumab; torvutatug samrotecan + carboplatin ± bevacizumab; torvutatug samrotecan + palacaparib
Platinum-resistant, relapsed, high-grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
NCT07402915
I
Torvutatug samrotecan/Torvutatug samrotecan + Itraconazole
Advanced solid tumors (advanced/metastatic ovarian cancer, HR+/HER2- breast cancer, TNBC, pancreatic cancer, prostate cancer, NSCLC, SCLC, gastric cancer, biliary cancer, cervical cancer, endometrial cancer, CRC, bladder cancer)
NCT04644068
Saruparib; saruparib + paclitaxel; saruparib + carboplatin ± paclitaxel; saruparib + T-DXd; saruparib + Dato-DXd; saruparib + camizestrant
fam-trastuzumab deruxtecan-nxki in US only; trastuzumab deruxtecan in other regions of world.
High-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer expressing high or low FRα levels
NCT07218809
Torvutatug samrotecan vs. mirvetuximab soravtansine in FRα-high and torvutatug samrotecan vs. chemotherapy in FRα-low platinum-resistant ovarian cancer
Advanced solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, metastatic urothelial carcinoma, BTCs)
NCT05489211
II
Dato-DXd; Dato-DXd + capecitabine or 5-FU; Dato-DXd + prednisone or prednisolone; Dato-DXd + carboplatin + bevacizumab followed by Dato-DXd + bevacizumab; Dato-DXd + bevacizumab + (5-FU + leucovorin or capecitabine); Dato-DXd+ 5-FU/leucovorin or capecitabine + bevacizumab; Dato-DXd + rilvegostomig or carboplatin/cisplatin
